The potential of gene therapy approaches for the treatment of hemoglobinopathies: achievements and challenges
Authors:
Open Access
- 31 July 2016
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 7 (5) , 302-315
Abstract
Hemoglobinopathies, including β-thalassemia and sickle cell disease (SCD), are a heterogeneous group of commonly inherited disorders affecting the function or levels of hemoglobin. Disease phenotype can be severe with substantial morbidity and mortality. Bone marrow transplantation is curative, but limited to those patients with an appropriately matched donor. Genetic therapy, which utilizes a patient’s own cells, is thus an attractive therapeutic option. Numerous therapies are currently in clinical trials or in development, including therapies utilizing gene replacement therapy using lentiviruses and the latest gene editing techniques. In addition, methods are being developed that may be able to expand gene therapies to those with poor access to medical care, potentially significantly decreasing the global burden of disease.Keywords
This publication has 84 references indexed in Scilit:
- In vivo genome editing using a high-efficiency TALEN systemNature, 2012
- Hematopoietic Stem Cell Transplantation in Thalassemia and Sickle Cell AnemiaCold Spring Harbor Perspectives in Medicine, 2012
- Induction of Fetal HemoglobinIn VivoMediated by a Syntheticγ-Globin Zinc Finger ActivatorAnemia, 2012
- In Situ Genetic Correction of the Sickle Cell Anemia Mutation in Human Induced Pluripotent Stem Cells Using Engineered Zinc Finger NucleasesStem Cells, 2011
- In vivo genome editing restores haemostasis in a mouse model of haemophiliaNature, 2011
- The Sleeping Beauty transposon system: a non-viral vector for gene therapyHuman Molecular Genetics, 2011
- Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemiaNature, 2010
- Control of fetal hemoglobin: new insights emerging from genomics and clinical implicationsHuman Molecular Genetics, 2009
- Conditional deletion of STAT5 in adult mouse hematopoietic stem cells causes loss of quiescence and permits efficient nonablative stem cell replacementBlood, 2009
- Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined FactorsCell, 2006